SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

$BBNX
Medical/Dental Instruments
Health Care
Get the next $BBNX alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Eventide Asset Management, LLC
 
Signature:/s/ Peter J. Luiso
Name/Title:Peter J. Luiso, General Counsel
Date:02/05/2025
 
Finny Kuruvilla, M.D., Ph. D.
 
Signature:/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:Finny Kuruvilla, M.D., Ph. D.
Date:02/05/2025
 
Robin C. John
 
Signature:/s/ Robin C. John
Name/Title:Robin C. John
Date:02/05/2025
Exhibit Information

EXHIBIT 1 - Filed Herewith

Get the next $BBNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BBNX

DatePrice TargetRatingAnalyst
2/24/2025Buy
BofA Securities
2/24/2025$30.00Buy
Lake Street
2/24/2025$25.00Buy
Stifel
2/24/2025$26.00Overweight
Piper Sandler
2/24/2025$28.00Outperform
Leerink Partners
2/20/2025$20.00Neutral
Ladenburg Thalmann
2/20/2025$20.00Neutral
Robert W. Baird
More analyst ratings

$BBNX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

    IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

    $BBNX
    Medical/Dental Instruments
    Health Care
  • Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by B

    $BBNX
    Medical/Dental Instruments
    Health Care

$BBNX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BBNX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BBNX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BBNX
SEC Filings

See more

$BBNX
Financials

Live finance-specific insights

See more
  • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

    IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

    $BBNX
    Medical/Dental Instruments
    Health Care